Artigo de um grupo de investigação do i3S vence 1ª edição do Prémio Cancro Gástrico IPO do Porto

envie a um amigo share this

Artigo de um grupo de investigação do i3S vence 1ª edição do Prémio Cancro Gástrico IPO do Porto

Quinta, 13.05.2021

O artigo intitulado "A panel of intestinal differentiation markers (CDX2, GPA33, and LI‑cadherin) identifies gastric cancer patients with favourable prognosis" do grupo Differentiation & Cancer, no i3S, foi galardoado com a primeira edição do "Prémio Cancro Gástrico IPO do Porto", um prémio para o melhor artigo em investigação em cancro gástrico publicado nos últimos 2 anos e atribuído pelo IPO do Porto. A cerimónia de entrega do prémio terá lugar no IPO do Porto, no próximo dia 31 de Maio. Utilizando as técnicas de imunohistoquímica baseada em fluorescência por multiplex combinada com análise digital de imagem e imunohistoquímica por cromogénio, os autores descreveram um painel de diferenciação intestinal em cancro gástrico composto pelos marcadores CDX2, GPA33 e LI-caderina e observaram que a expressão proteica reduzida ou negativa do painel de diferenciação intestinal identifica pacientes de cancro gástrico com níveis de sobrevida particularmente baixos.

 

Autores e afiliações:

Nair Lopes1,2,3,4,11, Christian Bergsland3,4, Jarle Bruun3,4, Merete Bjørnslett3,4, André Filipe Vieira1,2, Patrícia Mesquita1,2, Rita Pinto1,5,12, Rosa Gomes6,7, Bruno Cavadas1,2, Eric Bennett5, Luisa Pereira1,2, Ragnhild A. Lothe3,4,8, Raquel Almeida1,2,9,10, Leonor David1,2,9

1 – IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Rua Júlio Amaral de Carvalho, 45, 4200‑135 Porto, Portugal

2 – i3S (Instituto de Investigação e Inovação em Saúde), University of Porto, Rua Alfredo Allen, 208, 4200‑135 Porto, Portugal

3 – Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Nydalen, P.O. Box 4953, 0424 Oslo, Norway

4 – K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Nydalen, P.O. Box 4953, 0424 Oslo, Norway

5 – Departments of Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, Copenhagen Center for Glycomics, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

6 – Oncology Department, Centro Hospitalar de Trás-Os-Montes E Alto Douro, Avenida da Noruega, Lordelo, 5000‑508 Vila Real, Portugal

7 – Oncology Department, Centro Hospitalar de S. João, Alameda Prof. Hernâni Monteiro, 4200‑319 Porto, Portugal

8 – Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Blindern, P.O. Box 1171, 0318 Oslo, Norway

9 – Department of Pathology, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200‑319 Porto, Portugal

10 – Department of Biology, Faculty of Sciences, University of Porto, Rua Do Campo Alegre, s/n, 4169‑007 Porto,Portugal

11 – Present Address: Cancer Biology and Epigenetics Group, Research Centre of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Rua Dr. António Bernardino de Almeida, 4200‑072 Porto, Portugal

12 – Present Address: Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Nydalen, P.O. Box 4953, 0424 Oslo, Norway

 

Abstract: Gastric cancer is the fifth most common cancer and the third cause of global cancer mortality. CDX2 is an intestinal differentiation marker with prognostic value in gastric cancer and transcriptionally regulates the expression of glycoprotein A33 (GPA33) and liver intestine cadherin (LI-cadherin). This study evaluated the clinical significance of the combined expression of CDX2 and its targets GPA33 and LI-cadherin in gastric cancer by fluorescence-based multiplex immunohistochemistry together with digital image analysis and chromogenic immunohistochemistry in 329 gastric cancer samples arranged in tissue microarrays. Additionally, publicly available RNA-seq expression data from 354 gastric cancer samples from the TCGA database were used to validate the immunohistochemistry results. Expression of the three markers (CDX2, GPA33, and LI-cadherin) was strongly correlated, defining an intestinal differentiation panel. Low or negative protein expression of the intestinal differentiation panel identified patients with particularly poor overall survival, irrespective of the methodology used, and was validated in the independent series at the RNA-seq level. Expression of the intestinal differentiation panel (CDX2, GPA33, and LI-cadherin) defines a set of biomarkers with a strong biological rationale and favourable impact for prognostication of gastric cancer patients.

 

Revista: Gastric Cancer

 

Link: https://link.springer.com/article/10.1007/s10120-020-01064-6